RO6870810 is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs called Bromodomain and Extra-Terminal Protein (BET) Inhibitors.

SparkCures ID 277
Developed By Hoffmann-La Roche
Generic Name RO6870810
Treatment Classifications

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)


There are no resources, links or videos to display for this treatment.

SparkCures Verified

SparkCures is working closely with Hoffmann-La Roche to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners